<b>BNT162b2 2024-2025 Vaccine Effectiveness against COVID-19 in Children aged 6 months</b> – <b>17 years</b>
In a test-negative case-control design among children aged 6 months-4 years (n=11,878) and 5-17 years (n=16,687) in Kaiser Permanente Southern California, BNT162b2 2024-2025 effectiveness against hospitalization/emergency department/urgent care/outpatient was 36% (95% CI: -5-61%) and 42% (-2-67%), respectively suggesting pediatric COVID-19 vaccination remains beneficial.
Authors
- Bradley K. Ackerson (ORCID: https://orcid.org/0000-0002-0816-7345)
- Timothy B. Frankland (ORCID: https://orcid.org/0000-0002-0987-8405)
- Sara Y. Tartof (ORCID: https://orcid.org/0000-0003-2336-8476)
- Joann M. Zamparo
- Tara Ahi
- Laura Puzniak
- Jeff M Slezak
Institutions
- Kaiser Permanente (US)
- Pfizer (United States) (US)
- Bay Medical Center (US)
Publication Details
- Journal
- Journal of the Pediatric Infectious Diseases Society
- Published
- 2026-04-02
- DOI
- https://doi.org/10.1093/jpids/piag029
- Primary Topic
- Vaccine Coverage and Hesitancy
- Type
- article
- Field-Weighted Citation Impact
- 0.00